NCT04234113 2026-03-27
Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
Phase 1 Terminated
Clinical Trials
9 trialsNCT03447470 2025-01-29
Study to Evaluate the Safety and Tolerability of RXC004 in Advanced Malignancies
Redx Pharma Ltd
Phase 1 Completed
NCT01621568 2024-09-24
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01325441 2023-11-15
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02420691 2020-10-30
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02364076 2019-12-13
Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma
Georgetown University
Phase 2 Unknown
NCT01364727 2019-04-16
A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies
Stanford University
Phase 2 Completed
NCT01100944 2017-08-10
A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated